Resectable NSCLCs
Conditions
Interventions
Single arm:Adobeilimab puls chemotherapy neoadjuvant therapy, Q3W, 3 cycles
radical operation
Sponsors
Anhui Provincial Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-75, gender unlimited; 2.Primary resectable non-small cell lung cancer of stage IB(=4cm)-IIIA confirmed by histopathology or cytology 3.No previous local or systemic treatment for primary lung cancer; 4. At least one measurable lesion (according to RECIST 1.1); 5. Negative EGFR/ALK driver genes; 6.Ecog ps . 01; 7. Life expectancy = 3 months; 8.The functional level of organs must meet the following requirements: ANC = 1.5×109/L; PLT = 90×109/L; Hb = 90 g/L; TBIL = 1×ULN; ALT and AST = 1.5×ULN, ALP = 2.5×ULN; BUN and Cr = 1× ULN and creatinine clearance = 50 mL/min (Cockcroft-Gault formula); LVEF = 50%; Fridericia corrected QT interval (QTcF) for male < 450 ms and female < 470 ms; INR = 1.5 x ULN, ACTT = 1.5 x ULN. 9.Subjects sign informed consent and voluntarily join the study.
Exclusion criteria
Exclusion criteria: 1.Previous antitumor therapy for primary lung cancer, including chemotherapy, targeting, immunization or radiotherapy; 2.Subjects who are allergic or hypersensitive to therapeutic drugs or have autoimmune diseases; 3.Subjects who are allergic or hypersensitive to therapeutic drugs or have autoimmune diseases; Presence of third space effusion that cannot be controlled by drainage or other means (e.g., excessive pleural fluid and ascites) 4.Steroid treatment for more than 50 days, or long-term use of steroids is required; 5.Uncontrolled symptomatic brain metastases or mental abnormalities that do not correctly state subjective symptoms; 6.Other malignancies developed within 5 years prior to inclusion, except carcinoma in situ of the cervix or squamous or basal cell carcinoma of the skin previously treated for radical treatment; 7.Pregnant or lactating women who are fertile but refuse to take contraceptive measures; 8.Patients with severe heart disease or history, including a documented history of congestive heart failure, high-risk uncontrolled arrhythmias, medicated angina, clinically clear valvular heart disease, history of severe myocardial infarction, and intractable hypertension; 9.Have received a tissue/solid organ allograft; 10.Concomitant medical conditions (e.g., uncontrolled hypertension, diabetes, thyroid disease, etc.) that, in the investigator's judgment, pose a serious risk to the subject's safety or affect the subject's ability to complete the study. 11. Other conditions that the researchers determined were not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Major pathological response rate; | — |
Countries
China
Contacts
Public ContactAnqing Zhang
Anhui Provincial Cancer Hospital
Outcome results
None listed